The dedicated hub for news and updates coming directly out of the Technion – Israel Institute of Technology.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Hope for patients suffering from severe tissue damage: Technion researchers have developed an implantable tissue flap containing muscle and fat tissues alongside a hierarchical network of blood vessels and lymphatic vessels.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Hope for patients suffering from severe tissue damage: Technion researchers have developed an implantable tissue flap containing muscle and fat tissues alongside a hierarchical network of blood vessels and lymphatic vessels.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
How has evolution shaped viral infection? How does humanity cope with viral diseases? Why do vaccines work well against one disease but not another? Why are drugs that work against bacteria ineffective against viruses? And how optimistic can we allow ourselves to be about the future? These questions were addressed recently by Dr. Yotam Bar-On of the Ruth and Bruce Rappaport Faculty of Medicine at a Technion event.
Groundbreaking research reveals a self-regulating, implantable living technology that could offer hope for millions with diabetes and other chronic diseases.
